RelB
- Known as:
- RelB
- Catalog number:
- 000125A
- Product Quantity:
- 250ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- RelB
Related genes to: RelB
- Gene:
- RELB NIH gene
- Name:
- RELB proto-oncogene, NF-kB subunit
- Previous symbol:
- -
- Synonyms:
- REL-B
- Chromosome:
- 19q13.32
- Locus Type:
- gene with protein product
- Date approved:
- 1995-10-02
- Date modifiied:
- 2016-04-29
Related products to: RelB
Related articles to: RelB
- PM causes multifaceted detrimental effects on human health. Alveolar type II epithelial (AT-II) cells serve critical function in PM-induced airway inflammation. However, the mechanism remains unclear. - Source: PubMed
Publication date: 2026/09/16
Jin YanZhao YunWei ShihuiChen XingyuZhu KeXiong JuanQi RongbinZhang WenLai TianwenCao Chao - Cancer therapy-related cardiac dysfunction (CTRCD) remains a major limitation of modern oncology, potentially compromising cardiovascular prognosis, functional status, and continuation of effective anticancer therapy. Vericiguat, an oral soluble guanylate cyclase (sGC) stimulator, enhances nitric oxide (NO)-sGC-cyclic guanosine monophosphate (cGMP) signalling and has emerged as a biologically plausible candidate for translational evaluation in CTRCD. Chronic doxorubicin exposure reduces cardiac sGC activity, and genetic or pharmacological modulation of this pathway modifies experimental anthracycline injury. A 2024 peer-reviewed study in human AC-16 cardiomyocyte cells and primary skeletal-muscle cells showed increased cGMP and attenuation of NLRP3/MyD88-associated inflammatory and cytotoxic signalling with vericiguat. Two independent full-length studies published in 2026 extended this signal, implicating inhibition of ferroptosis through restoration of SLC7A11/GPX4-related defence and suppression of glycolysis, histone lactylation, and RELB-dependent inflammatory signalling. These findings strengthen mechanistic plausibility but remain preclinical. In heart failure, SOCRATES-REDUCED supported dose selection, VICTORIA demonstrated a modest reduction in cardiovascular death or first heart-failure hospitalization after recent worsening HFrEF, whereas VICTOR had a neutral primary endpoint in more stable ambulatory HFrEF; pooled analyses nevertheless suggest an overall treatment signal across the HFrEF risk spectrum. No randomized outcome trial has demonstrated efficacy specifically in CTRCD. ELEVATE (NCT05806138), a small randomized phase II trial in breast-cancer-associated CTRCD, remains without reported efficacy results as of 9 September 2026. Vericiguat should therefore be considered a biologically coherent and clinically testable strategy rather than an established cardio-oncology therapy. - Source: PubMed
Publication date: 2026/09/30
Pezzi LauraRossi DavideMagnano RobertaSaraullo SilvioD'Alleva AlbertoMarino Mario DiScollo ClaudioPierfelice FrancescaGenovesi EugenioRenda GiuliaGallina SabinaMarco Massimo Di - Resistance to inhibitors (BRAFi), alone or with MEK inhibitors (MEKi), limits durable responses in -mutant melanoma. To characterize resistance-associated cell-state evolution, we analyzed 674 melanoma cells from six mice bearing tumors from a single patient-derived V600E-mutant melanoma xenograft (PDX) lineage before treatment, during initial regression, at minimal residual disease, and at resistant regrowth. Unsupervised clustering based on a -centered network feature set comprising 2506 candidate genes identified six transcriptional states, which were characterized using transcriptomic analyses. Cluster 4 was detected exclusively at resistant regrowth, a phase marked by MAPK pathway reactivation, and exhibited enhanced JAK-STAT/interferon signaling and increased , , , , and regulon activities. Network inference predicted - and - regulatory links, suggesting candidate routes to MAPK reactivation through overexpression and -mediated bypass signaling. External analyses partially recapitulated the resistance-associated transcriptional program in independent melanoma cell-line datasets and yielded limited, inconclusive evidence for the predicted - association in public perturbation datasets. Cluster 2 represented a pre-existing proliferative state whose signature was associated with shorter progression-free survival in pretreatment clinical cohorts. Together, these findings distinguish a therapy-associated acquired-resistance state from a pre-existing proliferative resistance-associated state and nominate the predicted - and - links for functional validation. - Source: PubMed
Publication date: 2026/09/09
Fu HaoWang MengyaoZhu HaiboLi WeihuaShen XiaopeiYan HaidanHe Jun - Although periodontal ligament stem cells (PDLSCs) are pivotal for periodontal tissue regeneration, their regenerative capacity diminishes with the PDL maturity. To elucidate the mechanisms underlying this phenomenon, we performed single-cell RNA sequencing (scRNA-seq) on immature and mature human PDL tissues to characterize the heterogeneity and predict critical regulators affecting osteogenic capacity of PDLSCs. Subsequently, the predicted role of RELB was experimentally validated both in vitro and in vivo using small interfering RNA. The scRNA-seq analysis revealed significant heterogeneity within the PDLSC population. Notably, PDLSC-5 subtype, which exhibited osteogenic potential and positioned at the terminus of the pseudotime trajectory, was markedly reduced in mature PDL tissues. RELB was specifically overexpressed in PDLSC-5 and identified as a key transcription factor (TF) for this subcluster. Knockdown of RELB significantly inhibited the osteogenic differentiation capacity of PDLSCs in vitro and bone formation potential in vivo at both developmental stages. This inhibitory effect appears to be mediated, at least in part, through the downregulation of its target gene, superoxide dismutase 2 (SOD2). Our findings demonstrate that the proportion of PDLSCs with osteogenic ability significantly declines with maturity, accounting for the diminished regeneration capacity of mature periodontal tissue. Furthermore, RELB was identified as a crucial TF for maintaining the osteogenic potential of PDLSCs. These results provide a theoretical basis for strategies aimed at optimizing the bone regeneration capacity of PDLSCs. - Source: PubMed
Publication date: 2026/09/24
Shao XinWu FanSong YangGao PengQi KunWang Liying - Microbial short-chain fatty acids (SCFAs) regulate intestinal epithelial homeostasis and immune tolerance. Yet, the specific host effector genes that mediate these responses remain poorly defined, limiting the identification of biomarkers and therapeutic targets. - Source: PubMed
Publication date: 2026/09/08
Masood ZahraSarwar IqraSanam AyeshaZaidi AmberSadikan Muhammad Zulfiqah